Table 3: Intermediate or high-risk patient's sub analysis.
Global | Gleason < 7 | Gleason > 6 | p | |
Age | 63.79 ± 7.5 | 63.29 ± 7.5 | 65.59 ± 7.4 | 0.2 |
Prostate volume | Prostate volume | 47.86 ±24.8 | 42.18 ± 21.7 | 0.33 |
PSAd | 0.19 ± 0.19 | 0.18 ± 0.20 | 0.22 ± 0.16 | 0.48 |
PSA | 6.06 ± 1.9 | 5.7 ± 1.9 | 67.0 ± 1.6 | 0.01 |
Free PSA | 1.01 ± 0.61 | 0.99 ± 0.64 | 1.08 ± 0.48 | 0.52 |
Ratio PSA | 0.16 ± 0.07 | 0.16 ± 0.07 | 0.15 ± 0.04 | 0.27 |
-2proSPA | 16.88 ± 11.15 | 15.13 ± 9.09 | 23.17 ± 15.2 | 0.02 |
Ratio -2proPSA | 1.81 ± 1.08 | 1.75 ± 0.99 | 2.03 ± 1.34 | 0.26 |
PHI | 44.02 ± 26.04 | 41.03 ± 23.5 | 54.78 ± 31.7 | 0.02 |